Clinical Trials
23 trialsNCT02386800 2026-05-27
CINC424A2X01B Rollover Protocol
Novartis
Phase 4 Active not recruiting
NCT03975829 2026-05-11
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Recruiting
NCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT05853458 2026-04-30
HU-F-AIM
Novartis
Phase 4 Terminated
NCT06427811 2026-04-17
ASC4INDIA
Novartis
Phase 4 Completed
NCT06748001 2026-02-09
Avapritinib Rollover Study
Blueprint Medicines Corporation
Phase 4 Recruiting
NCT06290765 2025-07-31
PV
PharmaEssentia
Phase 4 Not yet recruiting
NCT01735955 2024-02-08
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Completed
NCT01957176 2022-12-30
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Phase 4 Completed
NCT02546674 2022-07-22
NILOdeepR
Novartis
Phase 4 Completed
NCT05367765 2022-05-10
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4 Not yet recruiting
NCT02228382 2021-12-30
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Pfizer
Phase 4 Terminated
NCT00980018 2021-07-01
MACS0999
Novartis
Phase 4 Completed
NCT01201811 2019-12-05
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
Celgene
Phase 4 Completed
NCT02204722 2018-06-15
IDEAL
Dong-A ST Co., Ltd.
Phase 4 Terminated
NCT01605981 2017-04-20
MACS1881
Novartis
Phase 4 Withdrawn
NCT00171899 2017-02-23
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
Novartis
Phase 4 Completed
NCT00786812 2017-02-23
MACS0439
Novartis
Phase 4 Completed
NCT01368523 2016-11-16
Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial
Novartis
Phase 4 Completed
NCT01043874 2016-04-08
MACS0911
Novartis
Phase 4 Completed
NCT01227577 2016-02-08
MACS1428
Novartis
Phase 4 Completed
NCT02317159 2014-12-15
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Cttq
Phase 4 Unknown
NCT00081926 2009-11-23
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Novartis
Phase 4 Completed